References
- Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, et al. Whole-body 16F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43: 325–9
- Wahl RL, Zasadnny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101–11
- Moon DH, Maddahi J, Silverman DHS, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39: 431–5
- Smith IC, Welch AE, Hutcheon AW, Payne S, Chilcott F, Walker S, et al. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of brest cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676–88
- Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28: 351–6
- Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast cancer. Anticancer Res 1997; 17: 1687–92
- Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer. The referring physician's perspective. J Nucl Med 2001; 42: 1334–7
- Gallowitsch H-J, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38: 250–6
- Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol 2004; 183: 479–86
- Siggelkow W, Zimmy M, Faridi A, Petzold K, Buell U, Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003; 23: 1859–67
- Couturier O, Jerusalem G, N'Guyen J-M, Hustinx R. Sequential positron emission tomography using [18F] fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006; 12: 6437–44
- Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–8
- Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumor markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging ;31 Suppl 2004; 1: S118–24
- Jansson T, Westlin JE, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 1995; 13: 1470–7